Gilead Sciences reported Q1 results (NASDAQ:), with an EPS of $2.12 better than the consensus estimate at $1.81. Comparable to $6.28 billion consensus estimate, revenue grew by 3% to $6.6 Billion.

Biktarvy sales increased 18% to $2.2Billion, while Descovy sales rose by 4% and Truvada sales fell 72% in the first quarter.

It expects Q2/22 to have EPS between $6.20 and $6.70, in comparison to $6.50. The revenue range is $23.8-23.43 billion, in contrast to $24.48 trillion. It expects to sell product between $23.8 billion-$24.3 billion. This includes Veklury sales of $2 billion.

Gilead shares were 15% lower year to date going into earnings results

By Davit Kirakosyan